Onconex Head and Neck Cancer (Germline)

Understanding Onconex Head and Neck Cancer (Germline)

Head and neck cancer (HNC) is the seventh most common cancer globally, accounting for more than 660,000 new cases and 325,000 deaths annually. Head and neck squamous cell carcinoma (HNSCC) comprises a heterogeneous group of tumors that arise from the squamous epithelium of the oral cavity, oropharynx, larynx, and hypopharynx. More than 90% of tumours in the head and neck are squamous carcinomas.

Complex chromosomal changes and gene copy number alterations are present across the spectrum of HNSCC and are evident in...

What does Onconex Head and Neck Cancer (Germline) measure?

The Onconex Head and Neck Cancer (Germline) test is a comprehensive Next Generation Sequencing (NGS) assay targeting 125 genes associated with head and neck cancers, providing detailed genetic insights to guide targeted therapy and improve patient outcomes.

The Onconex Head and Neck Cancer (Germline) test offers insights into the molecular underpinnings of tumor mutation genes, facilitating the identification of novel genetic aberrations and potential therapeutic targets. As targeted therapies become the new standa...